Media Newsroom of

TARA Biosystems

TARA Biosystems, Inc. provides predictive, in vitro human cardiac tissue models for use in drug discovery and safety assessment.

TARA Biosystems, Inc. Secures Exclusive Worldwide License to Columbia University Intellectual Property Relating to Engineered Human Cardiac Tissues

TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the execution of an exclusive worldwide license agreement with Columbia University for intellectual property relating to engineered…

TARA Biosystems Inc. Announces Issuance of US Patent for Biowire™ II Heart-on-a-Chip Platform

TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent 10,254,274 covering methods, compositions…

TARA Biosystems Biowire™ II Heart-on-a-Chip Platform Published in CELL

TARA Biosystems, Inc., a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the first peer-reviewed publication of its Biowire™ II platform by a team of researchers led by Milica Radisic,…

TARA Biosystems and Insilico Medicine Announce Drug Discovery Collaboration for Cardiac Disease

TARA Biosystems Inc., a company offering “heart-on-a-chip” tissue models for drug discovery and risk-assessment applications, and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases, announced today the launch of a collaboration to discover and develop…

TARA Biosystems Announces Launch of Cardiotype.Fo, Best-in-Class In Vitro Assay for Assessment of Cardiac Contractility

TARA Biosystems Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and development applications, announced today the launch of Cardiotype.Fo, the best-in-class in vitro system for assessment of cardiac contractility. Contractility of heart muscle tissue is a critically important measure…

TARA Biosystems' CEO Misti Ushio Named to Fast Company's Top 100 Most Creative People in Business

TARA Biosystems Inc., a company offering physiologically relevant, human “heart-on-a-chip” tissue-models for drug discovery and development applications, is proud to announce that TARA CEO Dr. Misti Ushio has been recognized by Fast Company as one of the Top 100 Most Creative…

TARA Biosystems Raises $9 Million Series A Financing

TARA Biosystems, Inc., a company developing physiologically relevant “heart-on-a-chip” tissue models for drug discovery, toxicology and translational medicine applications, announced today that it closed on a $9 million Series A financing. TARA Biosystems offers testing services on its human stem…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login